PLAU/uPA (active form), His, Human

PLAU/uPA (active form), His, Human

Plasminogen activator, urokinase (uPA) is a secreted serine protease, cleaving the sequence Cys-Pro-Gly-Arg560-Val561-Val-Gly-Gly-Cys in plasminogen to form plasmin. Dysregulation of PLAU is often accompanied by various cancers and PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC.
Z05758
¥69,021.00

Ask us a question
Product Introduction
Species Human
Protein Construction
PLAU/uPA (active form) (Ser21-Leu431, which consists of two chains: Long chain A (Ser21-Phe177) and chain B (Ile179-Leu 431). The longchain A is further cleaved to yield a short chain A (Lys156-Phe 177) and N-Terminus fragment (Ser21-Lys155))
Accession # P00749-1		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its ability to cleave a peptide substrate, N­carbobenzyloxy­Gly­Gly­Arg­7­amido­4­methylcoumarin (ZGGR­AMC). The specific activity is > 2000 pmol/min/μg. Test result meets the standard.
Expression System HEK293
Theoretical Molecular Weight 17.9 kDa (long chain A), 29.2 kDa (chain B) and 15.3 kDa (N-terminal fragment)
Apparent Molecular Weight The protein migrates to 30-38 kDa (chain B) and 17 kDa (N-terminal fragment) based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in 1% HCOOH, 1mM DTT (pH 3.0).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 1% HCOOH, 1mM DTT (pH 3.0).
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background Plasminogen activator, urokinase (uPA) is a secreted serine protease, cleaving the sequence Cys-Pro-Gly-Arg560-Val561-Val-Gly-Gly-Cys in plasminogen to form plasmin. Dysregulation of PLAU is often accompanied by various cancers and PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC.
Synonyms PLAU; Urokinase; ATF; UPA; URK; u-PA; BDPLT5; QPD

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.